With respect to PDAC, recent observations in a cohort of 493 (263 with PDAC) showed that THBS2 serum levels significantly differed and differentiated PDAC from high-risk individuals (familial pancreatic cancer patients) with a 55.9% test sensitivity (at 100% specificity; 100% PPV and 66.5% NPV). Here, THBS2 is linked to familial pancreatic carcinoma.